Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch

Robert W. Bolderman*, Jan Peter de Bruin, J. J. Rob Hermans, Mark J. Boerakker, Aylvin A. Dias, Frederik H. van der Veen, Jos G. Maessen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective: Clinical studies have demonstrated the efficacy of oral and intravenous amiodarone therapy to prevent postoperative atrial fibrillation. However, because of significant extracardiac side effects, only high-risk patients are eligible for prophylactic amiodarone therapy. This study addressed the hypothesis that atrium-specific drug delivery through an amiodarone-eluting epicardial patch reduces vulnerability to atrial tachyarrhythmias, whereas ventricular and plasma drug concentrations are minimized. Methods: Right atrial epicardiums of goats were fitted with electrodes and a bilayered patch (poly[ethylene glycol]-based matrix and poly[lactide-co-caprolactone] backing layer) loaded with amiodarone (10 mg per patch, n=10) or without drug (n=6). Electrophysiologic parameters (atrial effective refractory period, conduction time, and rapid atrial response to burst pacing) and amiodarone levels in plasma and tissue were measured during 1 month's follow-up. Results: Epicardial application of amiodarone-eluting patches produced persistently higher drug concentrations in the right atrium than in the left atrium, ventricles, and extracardiac tissues by 2 to 4 orders of magnitude. Atrial effective refractory period and conduction time increased, whereas rapid atrial response inducibility decreased significantly (P
Original languageEnglish
Pages (from-to)904-910
JournalJournal of Thoracic and Cardiovascular Surgery
Issue number4
Publication statusPublished - Oct 2010


Dive into the research topics of 'Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch'. Together they form a unique fingerprint.

Cite this